NERV (Minerva Neurosciences) Net Margin %: 0.00% (As of Mar. 2026)


NERV Minerva Neurosciences Inc NERV
32 GF Score
Price $4.32
! 1 Warning Sign
View Full Analysis

What is Minerva Neurosciences Net Margin %?

Minerva Neurosciences NERV -0.23% 32 Net Margin % is 0.00% as of Mar. 2026. GuruFocus rates NERV with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 947 Biotechnology companies, Minerva Neurosciences ranks worse than 105596.52% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Minerva Neurosciences's Net Income for the three months ended in Mar. 2026 was $-125.40 Mil. Minerva Neurosciences's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Minerva Neurosciences's net margin for the quarter that ended in Mar. 2026 was 0.00%.

The historical rank and industry rank for Minerva Neurosciences's Net Margin % or its related term are showing as below:


NERV's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -89.33
* Ranked among companies with meaningful Net Margin % only.

Minerva Neurosciences  (NAS:NERV) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Minerva Neurosciences Net Margin % Related Terms

Minerva Neurosciences Net Margin % Historical Data

* Premium members only.

The historical data trend for Minerva Neurosciences's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Minerva Neurosciences Net Margin % Chart

Minerva Neurosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Minerva Neurosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NERV vs YDES, CAMP, IKT: Net Margin % Comparison

For the Biotechnology subindustry, Minerva Neurosciences's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Minerva Neurosciences Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Minerva Neurosciences's Net Margin % distribution charts can be found below:

* The bar in red indicates where Minerva Neurosciences's Net Margin % falls into.


NERV
32GF Score
Minerva Neurosciences Inc NERV
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Minerva Neurosciences Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Minerva Neurosciences's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-293.423/0
= %

Minerva Neurosciences's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-125.404/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Minerva Neurosciences (NERV) has a Net Margin % of 0.00% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Minerva Neurosciences and its competitors. Over the past decade, Minerva Neurosciences' Net Margin % has ranged from 4.71 to 4.71. According to the industry distribution chart, Minerva Neurosciences ranks #999999 out of 947 companies in the Biotechnology industry.
Is Minerva Neurosciences' Net Margin % too high?
Minerva Neurosciences' current Net Margin % is 0.00%. Over the past 10 years, this metric has ranged from a low of 4.71 to a high of 4.71. Based on the distribution chart, Minerva Neurosciences ranks #999999 out of 947 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Minerva Neurosciences has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Minerva Neurosciences' Net Margin % compare to YDES and CAMP?
According to the Biotechnology industry distribution chart, Minerva Neurosciences ranks #999999 out of 947 companies for Net Margin %. This places Minerva Neurosciences in the lower half of its industry. Historically, Minerva Neurosciences' own Net Margin % has ranged from 4.71 to 4.71 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Minerva Neurosciences and its competitors. Minerva Neurosciences's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minerva Neurosciences stock overvalued right now?
Minerva Neurosciences (NERV) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Minerva Neurosciences' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Minerva Neurosciences (NERV), the current Net Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Minerva Neurosciences Business Description

Other Exchanges 4MNA:Germany
Address 1500 District Avenue, Burlington, MA, USA, 01803
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.
32GF Score

Get the complete analysis for NERV

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.32
Price